Trial Termination
Eli Lilly Withdraws $1.9B Phase 2b Obesity Trial Before Launching Enrollment
Eli Lilly; obesity drug; tirzepatide; bimagrumab; trial termination; phase 2b; Zepbound; type 2 diabetes; clinical trial; regulatory strategy
Actionable Insights Powered by AI
Eli Lilly; obesity drug; tirzepatide; bimagrumab; trial termination; phase 2b; Zepbound; type 2 diabetes; clinical trial; regulatory strategy